Taking liraglutide made people feel fuller and less hungry for food, even though they didn’t eat fewer calories than those on a diet, suggesting the drug directly affects appetite signals.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether GLP-1RAs consistently improve appetite ratings (fullness, prospective consumption) compared to dietary interventions across diverse populations with obesity and prediabetes.
A systematic review and meta-analysis of at least 15 RCTs comparing GLP-1RA monotherapy (liraglutide 1.8–3.0 mg/day or semaglutide 1.0–2.4 mg/week) to caloric restriction or placebo, using standardized VAS appetite scales as primary outcomes, with subgroup analysis by BMI and glycemic status.
An RCT would confirm whether liraglutide improves appetite ratings independently of caloric intake by comparing it to a matched-calorie diet.
A double-blind, parallel-group RCT with 100 adults with obesity and prediabetes, randomized to liraglutide 1.8 mg/day or isocaloric diet (same 390 kcal/day deficit) for 14 weeks, with daily VAS appetite ratings (fullness, hunger, prospective consumption) as primary outcomes.
A cohort study would assess whether individuals prescribed GLP-1RAs report sustained appetite changes over time compared to those using diet alone.
A prospective cohort study following 200 adults with obesity and prediabetes for 1 year, tracking GLP-1RA use versus dietary intervention and monthly VAS appetite ratings, adjusting for weight change and medication adherence.
A cross-sectional study could describe the association between GLP-1RA use and appetite ratings in a real-world population.
A cross-sectional survey of 800 adults with obesity and prediabetes in primary care, comparing VAS appetite scores between those currently using GLP-1RA and those using diet-only interventions, adjusting for BMI, age, and duration of treatment.
Expert consensus could summarize the biological plausibility of GLP-1RAs modulating appetite via hypothalamic pathways.
A narrative review by neuroendocrinologists synthesizing human and animal data on GLP-1 receptor expression in hypothalamic appetite centers and clinical appetite rating outcomes.